Small molecule · Inhibitor of KAT6A (MOZ; MYST3) (KAT6A) and KAT6B (MORF; MOZ2; MYST4) (KAT6B) · developed by Olema Pharmaceuticals
OP-3136 is an orally bioavailable inhibitor of the histone acetyltransferases KAT6A and KAT6B, which binds these enzymes and blocks acetylation of histones and other substrates. It is being studied in breast cancer, non-small cell lung cancer, and castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06784193 | Phase 1 | Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) | Recruiting | OLMA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)FulvestrantMetastatic Breast CancerPalazestrant
Updated Oct 25, 2026. Something wrong or missing? Report it on the OLMA page.
See OLMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OLMA catalysts and pipeline →